He discusses programs covering dry eye, ocular pain, AMD, geographic atrophy, and more. Plus, how he using Bausch + Lomb's expertise in the eye and investing in biotech technologies of the future.

Brent Saunders discusses the launch of MEIBO and XIIDRA, talks about priorities for 2024, and gives the latest on BeautyHealth and Roam.

Brent Saunders describes a recent deal Bausch + Lomb has made in dry eye disease and his goal to push further into retinal diseases as well.